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Results of allogeneic bone marrow transplantation for acute leukemia 
have improved in Europe with time -  a report of the Acute Leukemia 
Working Party of the European Group for Blood and Marrow 
Transplantation (EBMT)
F Frassoni, M Labopin, E Gluckman, HG Prentice, J-P Vernant, F Zwaan, A Granena, G Gahrton, 
T De Witte, A Gratwohl, J Reiffers and NC Gorin
Summary:
To evaluate whether the results of bone marrow trans-
1986 (P = 0.0004) and in younger patients 
(P -  10 4). However a better outcome alter 1986/87 was 
observed in patients receiving the same GVHD prophy-
plantation have improved in Europe with time, we ana- laxis: therefore, other unidentified factors resulting in
iyzed the outcome for 2195 patients with acute leuke- better patient care have also contributed to this. The
mia. 1405 had acute myeloid leukemia (AML) and 790 improved results of allogeneic BMT are entirely related
had acute lymphoblastic leukemia (ALL), and were alio- to a reduction in TRM without loss of the antileukemic
grafted in first complete remission between September effect since relapse incidence has not changed over the
1979 and December 1991 with marrow from an HLA- years.
identical sibling donor. We found a continuing improve- Keywords: allogeneic BMT; acute leukemia; improve­
ment more evident since 1987 for AML and since 1986 
for ALL. A substantial reduction in the 3 years trans­
plant related mortality (TRM): 26 vs 39% for AML 
( P -  10 A  and 25 vs 39 % for ALL (P = 1 0 4), has 
resulted in an increase of the 5-year actuarial leukemia- 
free survival (LFS). 57 vs 45% for AML {P <  10 4) and 
54 vs 45% {P ~ 10 4) for ALL. Four important changes 
have occurred. (1) Graft-versus-host disease (GVHD) 
prevention has involved an increased use of cyclosporin 
A (CsA) alone and subsequently its use in combination 
with methotrexate: this was associated with lower TRM 
both in AML and ALL; (2) Use of total body irradiation 
as pretransplant regimen has decreased; (3) a shorter 
interval from remission to BMT is more common; (4)
population of patients has undergone BMT.
were performed separately in
ment; EBMT
In the last 15 years allogeneic bone marrow transplant has 
been increasingly used in patients with acute leukemia with
y I 3an HLA compatible 
reduces the risk of relapse in some diseases. However,
tn ant related morti has . giving
rise to debate on merit of BMT particularly in first remis- 
-1 <> s jn ce  impr0ved results have also been reported with
an
Multivariate
AML
influenced 
younger age at
including CsA (P = 0.008), sex match other than female 
donor
and ALL. In AML four variables significantly
favorably: year of BMT OP = 10 4), 
T (P= 10 “), prevention of GVHD
chemotherapy7 or autologous bone marrow transplan­
tation.10 ^ There is currently no consensus on how to treat 
patients in first remission; several randomized trials have 
been devised to compare the three modalities: allogeneic 
BMT, autologous BMT and chemotherapy.
1 a retrospective ant
n
patients
in first remission (CR) in which we evaluated
outcome of allogeneic BMT in Europe with time.
male recipient (P ~ 0.002). The relapse 
incidence (RI) was lower in patients with FAB M l-2- Patients and methods
3 vs M4-5 (ƒ»
BMT (P 0.0004), younger
0.0004). The LFS improved by year of
= 1 0  4 ),at r (P The Acute Leukemia Working Party of the European Group
prevention of GVHD including CsA (/* = 0.01), FAB for Bone Marrow Transplantation (EBMT) has collected 
M l-2-3 (P = 0.03). In ALL, three variables were assoc- data from European centers since 1979. Data on patient and
iated with a T
LViVf'TUl
: year of BMT CP= 10 4), donor age and sex, patient disease, stage of the disease, 
10 4), sex combination other date of transplant (BMT), details on conditioning regimen,younger age at BMT (P
than female to male {P ~ 0.008). The LFS was better method of graft-versus-host disease (GVHD) prophylaxis,
incidence of acute and chronic GVHD, relapse, and final 
outcome were obtained from each center for every patient
Correspondence: Prof NC Gorin. EBMT Data Management Office, ( ( ’entre by annual questionnaire. Information on surviving patients
International grelle de moelle) and formation associée Claude Bernard de j undated evcrv Year
recherche sur les urelTcs de cellules souches héinaiopoiétiques, Institut des ‘ \ ‘  ^ ‘ , , A n-  ...
Cordeliers. 15 rue de l'i colc de Médecine. 75006 Paris. France , h e  Posent analysis concerns 2195 patients, 1405 With
Received 6 April 1995; accepted 27 July 1995 acute myeloid leukemia (AML) and 790 with acute lyin-
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phoblastic leukemia (ALL) (n = 790) allografted in first compared the characteristics of the patients in the two 
remission from September 1979 to December 1991 using cohorts: For AML, 648 patients were grafted before 1987
an HLA-identical sibling donor. and 757 after 1987. For ALL, 248 patients were grafted
The endpoints of the study were leukemia-free survival before 1986 and 542 after 1986. For AML, the TRM at 3 
(LFS), relapse incidence (RI) and transplant related years decreased from 39% before 1987 to 26% after 1987 
mortality (TRM).
LFS was defined as survival without evidence of 
leukemia.
TRM was defined as death while in complete remission; 
patients were censored at time of relapse or lost to 
follow-up.
(P <  10"4). The LFS increased from 45% before 1987 to 
57% after 1987 (P <  10~4) (Figure 1). For ALL, the TRM 
at 3 years decreased from 39% before 1986 to 25% after 
1986 (P <  10'4) and the LFS increased from 45% before 
1986 to 54% after 1986 (P = 0.004) (Figure 2).
The relapse incidence did not change over the years
For the RI, patients dying of either direct toxicity of the either in AML or ALL (Figures 3 and 4, respectively).
or any other cause not related to leukemia 
were censored.
All analyses were performed with the BMDP statistical 
package. Differences between groups were studied using 
the X2- statistics for qualitative variables. Kaplan-Meier 
curves for LFS, RI, and TRM were calculated using the 
product-limit method.14 The results were expressed as per­
centage ± standard error. The significance of differences 
between the curves was estimated by the log-rank test 
(Mantel-Cox). We analyzed AML and ALL separately.
We evaluated the influence on LFS, RI and TRM of sev­
eral characteristics of the disease by univariate analysis: 
year of transplant, age, sex, FAB classification for AML, 
interval between diagnosis and BMT, pretransplant regimen 
(total body irradiation _(TBI) vs no TBI), sex match, GVHD 
prevention (cyclosporin A (CsA), methotrexate (MTX), 
CsA-MTX, T depletion, other), score of acute GVHD (0-  
1 vs >  1 ), incidence of chronic GVHD.
All variables differing significantly between the two 
groups were included in a multivariate analysis.15 In multi­
variate analysis the year of transplant was analyzed as a 
continuous variable.
Results
vvement w
We analyzed the outcome for patients year by year, and 
although we have found a continuous improvement over 
the years, a more consistent improvement in the results was
since 1987 for AML and since 1986 for ALLreeor
(Table 1 ). To assess the reason for this improvement, we
Table 1
ihe year of iransplant
LFS and TRM  2 years after allogeneic BM T according to
I - — , *  .  .  i  i  i * .  . .  .  . . .  -  . . . . .  ,  ,
AML
» » ,  - - — ■- ------------ *  . ----------- 1 . , »  - -
ALL
—  ■■■ » ' « v - «
No. o f LFS TRM No. o f LFS TRM
patienrs patients
<  1982 114 45 ± 5 44 ± 5 18 39 ± 11 48 ± 12
1982-84 240 47 ± 3 39 ± 3 143 48 ± 4 43 ± 4
1985 149 50 ±  4 33 ± 4 87 52 ±  5 37 ± 5
1986 145 49 ± 4 35 ± 4 83 60 ± 5 23 ± 5
1987 136 55 ±  4 29 ± 4 104 50 ±  5 21 ± 4
1988 188 58 ± 4 26 ± 3 96 60 ± 5 24 ± 4
1989 133 65 ± 4 18 ± 3 77 61 ± 6 24 ±  5
1990 148 65 ±  4 17 ± 3 83 58 ± 6 19 ± 4
1991 152 54 ±  5 25 ± 4 99 53 ± 6 33 ± 6
1992 106 70 ±  6 19 ± 5 92 65 ± 5 23 ± 6
LFS
1
0.8
0.6
0.4
0.2
0
57%
45%
I
39%
26%
LFS: P< IO”4 TRM: P<  10"4 Years
0
TRM
1
— before 1987
2 3 4
after 1987
5
Figure  1 Leukemia-free survival and transplant-related 
ents with AML allografted in CR1.
of pati-
LFS
1.00
0.80
0.60
0.40 mm t e  «** _ — r 39%
0.20
0.00
25%
LFS: P= 0.004 TRM: P< 10"4
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o 1
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F ig u re 2 LFS and TRM of patients with ALL allografted in CRI.
1
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Figure  3 Relapse incidence in patients allografted for AML in CRl .
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Figure 4 Relapse incidence in patients allografted for ALL in CR2.
Changes in treatment strategies
The two cohorts of patients differed in four characteristics 
(Table 2 and 3): in the second period, patients were older, 
the interval from diagnosis to BMT was shorter, TBI was 
used less frequently, and GVHD prophylaxis consisted of 
more CsA + MTX. The distribution of other variables was 
even, including the time to reach CR, and use of T cell 
depletion.
Tabic 3 Distribution of patients with ALL allografted in first
remission
v  January After January I)
v  . . — ' i .. W A— • —r ” V • • • •• ...... t. • - • — • • . V ..n- V
/ <AS’6 m ’6
No. of patients 248 542
Follow-up (months) 93(10 168) 3 8 (2 8 5 ) < 0.0001
Age at transplant (years) 21(1 43 ) 23( 1 51 ) 0.07
Male/female 162/86 3 6 0 /182 0.7ft
Sexmatehing (donor-recipient)
i, « i ; 
M/M 36 37 0.94
F/M 30 28
M/F 16 18
F/F 17 17
TBI (%) 99 94 0.001
GVDH prevention {%)
CsA 35 9 • 0.0001
MTX *> i 3H *
CsA +MTX
a. • ^
49
T depletion ± other 28  ^n to **
Other 12 16
Interval from diagnosis to 169(53-2756) 141(57 3595 ) 0.0004
BMT (days)
Acute GVHD score >  1 (7c) 28 25 0.29
Chronic GVHD (%) 16 9 0.003
Un i va ri a te anal vs is
By univariate analysis, we evaluated the influence on LFS, 
RI and TRM of several disease characteristics: year of 
transplant, age, sex, FAB classification for AML, interval 
between diagnosis and BMT, pretransplant regimen (total
CsA-MTX, T depletion,
(0-1 vs >  1), incidence of chronic GVHD.
i r '  /
Risk factors fo r  acute myeloid leukemia (AML)
body irradiation 
prevention
vs no TBI), sex match, GVHD The following prognostic factors were 
A (CsA). methotrexate (MTX). TRM was higher in older patients (P
in *
, ti'
female donor to male recipient
10 4 ) and in
was in
0.01). It
Table 2
remission
« I  I * patients with AML allografted in first (P <  10 4) and in patients receiving e
No. of patients 
Follow-up 
Age at u1 ant (years)
n
Female 
FAB classification
F/M
M/F
TBI {%)
s - . l l )
CsA
MTX
CsA + MTX
Interval from du*« 
BM T (days)
sis to
score 
Chronic GVHD(%)
ji»"' i ( % )
Before January After January
19R7
P
• t .  - - ............ ..
648 
84 (2™167) 
25(I 52)
757 
29 ( 1-73) 
29(1-56)
O.OOOI 
: 0.0001
325
323
0.54
365
36 0,65
i 8
n
30 0.73
26
24
98
1 1 
j i *  *  *
^ J
11 
I  * •# 0.0001
31
31
6
i l  
é s»  th *
10
11 
1
54
20
14
0.0001
163(31 3910) 150 (49-3776) 0.01
31
19
">S ** * ‘ 
11 K
0.02 
0.
I B f i «
exate
(P <  1 0 ) .  The RI was higher in M4 and M5 (P = 0.002)
and in the absence of severe acute (P  = 0.03) or chronic 
(P <  10 4) GVHD. As a
, a I■j classification
1er age of 4 rcci pi
absence of severe acute tc
M5.
prevention o f  GVHD  
with CsA + MTX, all resulted in a better LFS ( /’ = 0.0005, 
p  = 0.04, P <  10 \ 10 4, respectively).
Risk factors for  acute lymphoblastic leukemia (ALL)
The following prognostic factors were identified in ALL: 
TRM was higher in older p a °  <  ln 4 nul in the
female donor to male recipient combination (P «= 0,008),
and lower in patients receiving CsA alone or in combi­
nation with MTX. It was lower in the
GVHD (P <  10 4). The RI was higher in the 
severe acute (P = 0 .0 i) or chronic (P = 0.04) GVHD. As a
« *3% * J IS*. tV*
tcute GVHD resulted in better LFS (P <  10 4
TImpact o f  the use of MTX, CsA and CsA + MTX 
cell depletion on TRM, RI and LFS
In AML the actuarial 3 years TRM was 45, 32, 21 and
with MTX, CsA, CsA + MTX and T cell depletion
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Discussionrespectively (P <  10"4); the RI was not significantly differ­
ent; the LFS was 43, 49, 62 and 44% (P <  10~4).
In ALL the actuarial 3 years TRM was 41, 34, 24 and The aim of this study was to determine whether outcome
29% with MTX, CsA, CsA + MTX and T cell depletion has improved during the last decade for patients with acute 
respectively (P = 0.04); the RI was 21, 25, 30 and 31% leukemia allografted in first remission. There has been a
(P = 0.46); the LFS was 47, 49, 53 and 49% (P = 0.27).
Other reasons fo r  the improvement
To further evaluate whether the improvement with time 
also resulted from reasons independent of factors that 
changed over time, we analyzed the outcome of a more 
homogenous subgroup: patients less than 40 
receiving the same GVHD prophylaxis.
In AML, comparison of TRM for the two periods in the 
groups receiving the same prophylaxis, CsA alone and T 
cell depletion, showed a trend in the direction of a lower 
TRM in the latter period (P = 0.053, P = 0.06 respectively). 
We could not compare the TRM before and after 1987 in 
patients receiving the CsA + MTX combination because the 
number of patients treated before 1987 was too small 
(n = 37).
With ALL, comparison of TRM for the two periods in 
the groups receiving the same prophylaxis showed a sig­
nificant (P = 0.02) reduction in those receiving T depleted 
marrow and a trend (P = 0.17) in those receiving CsA 
alone. Only six patients received CsA + MTX before 1986, 
so that evolution of TRM over years for patients receiving 
this combination was not possible.
Causes of transplant related mortality
We have analyzed, year by year, the following causes of 
death: interstitial pneumonitis, acute and chronic GVHD, 
veno-occlusive disease, infection, graft failure and 
hemorrhagic death. Other less frequent causes were 
grouped as miscellaneous. The relative distribution of each 
of these causes of TRM did not vary over the years. Instead, 
it was global TRM that was reduced.
continuous improvement which became more obvious after 
1986/7: overall, the chance of being disease-free 5 years 
after allogeneic BMT using an HLA compatible sibling 
donor was 57% after 1987 v„v 45% before 1987 for AML, 
54% after 1986 vw 45% before 1986 for ALL. This was 
due to a decrease in TRM with no change in relapse rate. 
The fact that the European centers succeeded in reducing 
the toxicity of the procedure without loss of its antileu­
kemic effect should be considered a relevant step forward 
in the clinical practice of allogeneic BMT. The decrease in 
TRM itself was at least in part due to to a reduction in the 
incidence and severity of acute GVHD in AML and chronic 
GVHD in both AML and ALL. The relative prevalence 
of the causes of death did not vary over the time period 
studied; rather, reduction of mortality arose from a global 
diminution of severe complications of BMT.
Four important changes have occurred: increased use of 
cyclosporin A, initially alone and subsequently in combi­
nation with methotrexate, decreasing use of total body 
irradiation as pretransplant conditioning, shorter interval 
from remission to BMT, and an older population of patients 
undergoing BMT. The older age of patients transplanted 
after 1986-1987 would have been expected to produce a 
higher TRM; this was not the case, further emphasizing 
improvements achieved. Earlier transplantation after 1986- 
1987 indicates selection of a group of patients, per se at 
greater risk of relapse compared with years;
instead, there was no increased risk of relapse. Since there 
is increasing evidence that very prolonged LFS can be
obtained in selected AML with chemo-
Mu Itiva ri a te an a I vs es
All variables found to have an impact on outcome and vari­
ables differing in distribution among the two cohorts were 
included in the multivariate analysis: year of BMT, sex, ate was associated with reduced TRM and better LFS. This
therapy,21,22 it is likely that in recent years patients undergo­
ing BMT bear worse risk factors than in the previous time 
cohort. Altogether, these data show that with allogeneic 
BMT, the interval between diagnosis and BMT does not 
have the same relevance as in the 
secondly
firming that a shorter disease duration is associated with 
lower morbidity at transplant, as already
CML patients.16 
Cyclosporin A alone or in combination with methotrex-
with reduced TRM, con
age, interval between diagnosis and BMT, acute GVHD 
prevention (CsA and CsA + MTX vs other), FAB classifi­
cation for AML (M4-5 v.v other), TBI (yes v„y no).
was observed both in AML and ALL but the effect of the 
combination of CsA + MTX is more noticeable in AML. 
Since the introduction of CsA and CsA + MTX is closely
Table 4 summarizes the results of multivariate analyses linked with year of transplant it is difficult to establish the
in AML and ALL. In AML, four variables favorably influ- respective impact on results. Nevertheless, a progressive
enced TRM: year of BMT, younger age at BMT, prevention improvement relating to year of BMT is observed by ana-
o f GVHD including CsA, sex match other than female lyzing only patients who received either CsA alone or those
donor to male recipient. The RI was lower in patients with receiving T cell depleted marrow.
FAB M 1 -2-3 vs M4-5. LFS was improved by year of BMT, Since better GVHD prevention alone did not account for
younger age at BMT, prevention of GVHD including CsA, the improvement, it is likely that several factors together 
FAB M 1-2-3. account for the more recent improved results. The expertise
In ALL, three variables were associated with a lower of individual centers may have improved globally with bet-
TRM: year of BMT, younger age at BMT, sex combination 
other than female to male. The LFS was better after 1986 
and in younger patients (Table 4).
ter supportive care and improved prevention of major com­
plications such as cytomegalovirus,17 pneumonitis and 
veno-occlusive disease of the liver. Centers may also have
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Table 4 Factors found by multivariate analysis to influence leukemia-free survival, relapse incidence and transplant related mortality in the evolution 
of allogeneic bone marrow transplantation for acute leukemia in Europe
AML ALL
Variables RR P Variables
LFS
ni A > i , mr*- ■ n ■"■»imf.i % ,n »M i w . é a % a -y» ■ '. * fcit.i.i ■ . . ■ 1, » w - «-%■>— -■« ‘ «  -« . «Te» w —
Year of BMT (continuous) 0.94 <0.0001 Year of BMT (continuous)
Age at BMT (continuous) 1.02 <0.0001 Age at BMT (continuous)
CsA or CsA + MTX v.v other 0.8 0.02
M4-5 vs other 1.24 0.13
RI
M4-5 v.v other 1.63 <  0.0001 No factor significant
TRM
Year of BMT (continuous) 0.89 <0.0001 Year of BMT (continuous)
Age at BMT (continous) 1.03 <0.0001 Age at BMT (continuous)
CsA or CsA + MTX v.v other 0.77 0.03 Female donor to male recipient
Female donor to male recipient vs other 1.47 0.002
i  • k i t m  K * • ! ■ .. . i f
RR
0.93 
1.03
0.9
1.04
1.5
P
0.01 
0.0001
*v•>+ 0.0001
0.0001
0.09
RR = relative risk.
found an optimal balance for combination of conditioning 
therapy and GVHD prophylaxis.
In this European series o f patients, the combination 
CsA + MTX was not associated with increased risk of  
relapse: this is in keeping with some18 and in contrast with 
other reports.19 Severe GVHD dramatically increases TRM 
and, in spite of the beneficial effect of reducing relapse risk 
it remains associated with poorer LFS.
In keeping with previous reports,2 the present analysis 
confirms that BMT is better tolerated by younger patients, 
that the risk of relapse is higher for M4 and M5 and that 
the TRM is higher following BMT with a female donor to 
a male recipient. In this study the subtype M4-5 was also 
associated with worse LFS.
In conclusion, the present study shows that the outcome 
for patients with acute leukemia undergoing allogeneic 
BMT from their HLA identical sibling has improved con­
siderably over the years both in AML and ALL. This con­
firms the place of allogeneic BMT in the treatment o f acute 
leukemia, and currently about 1/3 patients who complete 
their post-remission treatment undergo allogeneic trans­
plant.1-1 Only the results of allogeneic BMT in the past 5 
years should be considered from now on, because o f the 
recent improvements in results. Nonetheless, since other 
treatment modalities,10,11,20 “-1 have also shown improved
results, the final ‘best c 
of debate.
•apy still remains a matter
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